BIT:PHIL - Philogen Stock Price & Analysis

About Philogen (BIT:PHIL)

(BIT:PHIL) Philogen S.p.A., a biotechnology company, develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company focuses on developing immunocytokines for oncology and in chronic inflammatory diseases. It is developing NIDLEGYTM (DAROMUN), an immunocytokine product used as a neoadjuvant intralesional treatment for melanoma patients with locoregional disease that is in phase III clinical trial for intralesional application and phase II clinical trial to treat non-melanoma skin cancer; FIBROMUN, a human immunomodulatory product consisting of the human anti-EDB antibody L19 to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and DARLEUKIN (L19IL2), a human immunostimulatory product consisting of the human anti-EDB antibody L19, which is in phase II clinical trial for the treatment of metastatic non-small cell lung cancer. The company is also developing DODEKIN, a human immunostimulatory product that comprises vascular targeting antibody fused to the human cytokine interleukin-12 that is in phase I clinical trial to treat advanced solid carcinomas; DEKAVIL (F8IL10), an anti-inflammatory product, which is in phase 2 clinical trial for the treatment of chronic inflammation; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressing solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. Philogen S.p.A. was founded in 1996 and is based in Sovicille, Italy.

PHIL Stock Price

Statistics Highlights (BIT:PHIL)

Shares Outstanding	40.51M	Beta	-
Public Float	3.16M	P/E Ratio	-
% Short of Float	-	Dividend (Yield)	-
Held by Insiders	43.22%	Ex-Dividend Date
Held by Institutions	3.90%	IPO Date	-

Explore More on "Statistics" Section

PHIL Financial Summary

|

	Dec 21	Dec 20	Dec 19
Revenue	€2.50M	€4.78M	€
EBITDA	€-12.97M	€-10.53M	€
Net Income	€-15.72M	€-13.29M	€
Total Assets	€132.75M	€85.47M	€
Total Cash	€8.88M	€11.96M	€
Total Debt	€	€	€

	Dec 21	Sep 21	Jun 21
Revenue	€	€	€
EBITDA	€	€	€
Net Income	€	€	€
Total Assets	€132.75M	€	€139.58M
Total Cash	€8.88M	€	€21.51M
Total Debt	€	€	€

(BIT:PHIL) Stock Price FAQs

What is today's stock price of Philogen (BIT:PHIL)?

The current stock price of Philogen (BIT:PHIL) is €14.36.
Today PHIL stock price opened at €14.30 after previous close of €14.30.
During the day, Philogen stock quote has varied from a low of €14.14 to a high of €14.36.

What is Philogen's 52-week change?

PHIL 52-week high stock quote is €15.68, which is 9.20% above the current share price.
The Philogen (BIT:PHIL) 52-week low stock price is €13.00, which is 9.50% below the current share price.

Philogen (BIT:PHIL) FAQ

How Much is Philogen Worth?

Philogen's worth today based on market capitalisation is €579.33M

How much dividend does Philogen Pay?

The current annualized dividend payout for PHIL stock is €0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Philogen's "Dividend" Section

What is Philogen’s Price to Earning (PE) ratio?

PHIL stock also has a Price to Sales (P/S) ratio of 116.71.

What is the Philogen's ticker?

Philogen trades on the Milan stock market in Italy under the ticker symbol "PHIL". Philogen’s stock symbol can also be displayed as "BIT:PHIL".

Who are the owners of Philogen?

Philogen (BIT:PHIL) is owned by 3.90% institutional shareholders and by 43.22% insiders. The rest is owned by the public.
Explore More Details on Philogen's “Ownership” Section

Who are the key executives of Philogen (PHIL)?

Philogen's key executive team includes the following managers:

Mr. Duccio Neri, Co-Founder & Exec. Chairman (NA)
Prof. Dario Neri Ph.D., Co-Founder, CEO , CSO, Pres of the Scientific Advisory Board & Director (1963)
Mr. Giovanni Neri, Co-Founder, Head of IP & Licensing and Director (NA)
Ms. Laura Baldi, Chief Financial Officer (NA)
Dr. Alfredo Covelli M.D., Chief Medical Officer (NA)
Mr. Jacopo Piazzi Ph.D., Head of Clinical Operations (NA)

What is Philogen’s Sector & Industry Classification?

Philogen (BIT:PHIL) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Philogen?

Currently the number of employees working for Philogen is 130.

Where are Philogen's Headquarters?

Philogen (BIT:PHIL) is headquartered in SI, Italy.

What are Philogen's Address and Phone Number?

Philogen’s mailing address is Via Bellaria, 35, Sovicille, SI, Italy, 53018.
The company’s phone number is 39 0577 17816.

What is the official website for Philogen?

Philogen’s official website is https://www.philogen.com

Philogen Stock (BIT:PHIL)